<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS108922</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.17.423313</article-id>
<article-id pub-id-type="archive">PPR256267</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A human coronavirus evolves antigenically to escape antibody immunity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Eguia</surname>
<given-names>Rachel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crawford</surname>
<given-names>Katharine H. D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stevens-Ayers</surname>
<given-names>Terry</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelnhofer-Millevolte</surname>
<given-names>Laurel</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greninger</surname>
<given-names>Alexander L.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Englund</surname>
<given-names>Janet A.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boeckh</surname>
<given-names>Michael J.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bloom</surname>
<given-names>Jesse D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Basic Sciences and Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA</aff>
<aff id="A2">
<label>2</label>Department of Genome Sciences, University of Washington, Seattle, WA, USA</aff>
<aff id="A3">
<label>3</label>Medical Scientist Training Program, University of Washington, Seattle, WA, USA</aff>
<aff id="A4">
<label>4</label>Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA</aff>
<aff id="A5">
<label>5</label>Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA</aff>
<aff id="A6">
<label>6</label>Seattle Children’s Research Institute, Seattle, WA USA</aff>
<aff id="A7">
<label>7</label>Department of Pediatrics, University of Washington, Seattle, WA USA</aff>
<aff id="A8">
<label>8</label>Howard Hughes Medical Institute, Seattle, WA 98109</aff>
<author-notes>
<corresp id="CR1">
<label>#</label>Corresponding author. <email>jbloom@fredhutch.org</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>24</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>18</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">There is intense interest in antibody immunity to coronaviruses. However, it is unknown if coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this question by characterizing the historical evolution of human coronavirus 229E. We identify human sera from the 1980s and 1990s that have neutralizing titers against contemporaneous 229E that are comparable to the anti-SARS-CoV-2 titers induced by SARS-CoV-2 infection or vaccination. We test these sera against 229E strains isolated after sera collection, and find that neutralizing titers are lower against these “future” viruses. In some cases, sera that neutralize contemporaneous 229E viral strains with titers &lt;1:100 do not detectably neutralize strains isolated 8–17 years later. The decreased neutralization of “future” viruses is due to antigenic evolution of the viral spike, especially in the receptor-binding domain. If these results extrapolate to other coronaviruses, then it may be advisable to periodically update SARS-CoV-2 vaccines.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">The SARS-CoV-2 pandemic has caused an urgent need to determine how well antibody immunity protects against SARS-CoV-2 infection. The evidence so far is promising.</p>
<p id="P3">Neutralizing and anti-spike antibodies elicited by natural infection correlate with reduced SARS-CoV-2 infection of humans (<xref ref-type="bibr" rid="R2">Addetia et al., 2020</xref>; <xref ref-type="bibr" rid="R50">Lumley et al., 2020</xref>), and vaccines that elicit such antibodies protect humans with high efficacy (<xref ref-type="bibr" rid="R59">Polack et al., 2020</xref>). These findings in humans are corroborated by a multitude of animal studies showing that neutralizing antibodies to the SARS-CoV-2 spike protect against infection and disease (<xref ref-type="bibr" rid="R4">Alsoussi et al., 2020</xref>; <xref ref-type="bibr" rid="R52">McMahan et al., 2020</xref>; <xref ref-type="bibr" rid="R79">Walls et al., 2020</xref>; <xref ref-type="bibr" rid="R86">Zost et al., 2020</xref>).</p>
<p id="P4">However, humans are repeatedly re-infected with the “common-cold” coronaviruses 229E, OC43, HKU1, and NL63 (<xref ref-type="bibr" rid="R19">Edridge et al., 2020</xref>; <xref ref-type="bibr" rid="R28">Hendley et al., 1972</xref>; <xref ref-type="bibr" rid="R68">Schmidt et al., 1986</xref>). For instance, serological studies suggest that the typical person is infected with 229E every 2–3 years (<xref ref-type="bibr" rid="R19">Edridge et al., 2020</xref>; <xref ref-type="bibr" rid="R68">Schmidt et al., 1986</xref>), although a lower infection rate and no 229E re-infections were reported in a 4-year study that identified infections by the criteria of a positive PCR test in the context of respiratory illness (<xref ref-type="bibr" rid="R3">Aldridge et al., 2020</xref>). In any case, the fact that common-cold coronavirus re-infections occur at some appreciable rate has led to concerns that coronavirus immunity is not “durable.” These concerns initially focused on the possibility that the immune response itself is not durable (<xref ref-type="bibr" rid="R34">Ibarrondo et al., 2020</xref>). This possibility now seems less likely, as SARS-CoV-2 infection induces neutralizing antibodies and memory B cells with dynamics similar to other respiratory viruses (<xref ref-type="bibr" rid="R14">Crawford et al., 2020a</xref>; <xref ref-type="bibr" rid="R24">Gaebler et al., 2020</xref>; <xref ref-type="bibr" rid="R63">Rodda et al., 2020</xref>; <xref ref-type="bibr" rid="R78">Wajnberg et al., 2020</xref>).</p>
<p id="P5">But there is another mechanism by which viruses can re-infect even in the face of long-lived and effective antibodies: antigenic evolution. For example, infection with influenza virus elicits antibodies that generally protect humans against that same viral strain for at least several decades (<xref ref-type="bibr" rid="R13">Couch and Kasel, 1983</xref>; <xref ref-type="bibr" rid="R84">Yu et al., 2008</xref>). Unfortunately, influenza virus undergoes rapid antigenic evolution to escape these antibodies (<xref ref-type="bibr" rid="R7">Bedford et al., 2014</xref>), meaning that although immunity to the original viral strain lasts for decades, humans are susceptible to infection by its descendants within about 5 years (<xref ref-type="bibr" rid="R13">Couch and Kasel, 1983</xref>; <xref ref-type="bibr" rid="R60">Ranjeva et al., 2019</xref>). This continual antigenic evolution is the reason that the influenza vaccine is periodically updated.</p>
<p id="P6">Strangely, the possibility of antigenic evolution by coronaviruses has received only modest attention, perhaps because coronaviruses have lower mutation rates than other RNA viruses (<xref ref-type="bibr" rid="R16">Denison et al., 2011</xref>; <xref ref-type="bibr" rid="R67">Sanjuán et al., 2010</xref>). However, mutation rate is just one factor that shapes antigenic evolution; influenza and measles virus both have high mutation rates, but only the former undergoes rapid antigenic evolution. Furthermore, the assumption of minimal coronavirus antigenic evolution is not supported by the limited evidence to date. In the 1980s, human-challenge studies found that individuals infected with one strain of 229E were resistant to re-infection with that same strain, but partially susceptible to a different strain (<xref ref-type="bibr" rid="R61">Reed, 1984</xref>). Additional experimental studies suggest that sera or antibodies can differentially recognize spike proteins from different 229E strains (<xref ref-type="bibr" rid="R69">Shirato et al., 2012</xref>; <xref ref-type="bibr" rid="R82">Wong et al., 2017</xref>). From a computational perspective, several studies have reported that the spikes of 229E and OC43 evolve under positive selection (<xref ref-type="bibr" rid="R12">Chibo and Birch, 2006</xref>; <xref ref-type="bibr" rid="R39">Kistler and Bedford, 2020</xref>; <xref ref-type="bibr" rid="R62">Ren et al., 2015</xref>), which is often a signature of antigenic evolution.</p>
<p id="P7">Here we experimentally assess whether coronavirus 229E escapes neutralization by human polyclonal sera by reconstructing the virus’s evolution over the last several decades. We show that historical sera that potently neutralize virions pseudotyped with contemporary 229E spikes often have little or no activity against spikes from 229E strains isolated 8–17 years later. Conversely, modern sera from adults generally neutralize spikes from a wide span of historical viruses, whereas modern sera from children best neutralize spikes from recent viruses that circulated during the children’s lifetimes. These patterns are explained by antigenic evolution of the spike, especially within the receptor-binding domain. If SARS-CoV-2 undergoes similarly rapid antigenic evolution, then it may be advisable to periodically update vaccines to keep pace with viral evolution.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<sec id="S3">
<title>Phylogenetic analysis of 229E spikes to identify historical strains for experimental study</title>
<p id="P8">We focused our studies on the viral spike protein because it is the main target of neutralizing antibodies (<xref ref-type="bibr" rid="R77">Tortorici and Veesler, 2019</xref>), and because anti-spike antibodies are the immune parameter best established to associate with protection against coronavirus infection in humans (<xref ref-type="bibr" rid="R2">Addetia et al., 2020</xref>; <xref ref-type="bibr" rid="R9">Callow, 1985</xref>; <xref ref-type="bibr" rid="R10">Callow et al., 1990</xref>; <xref ref-type="bibr" rid="R50">Lumley et al., 2020</xref>; <xref ref-type="bibr" rid="R59">Polack et al., 2020</xref>).</p>
<p id="P9">Because SARS-CoV-2 has circulated in humans for less than a year, we needed to choose another coronavirus with a more extensive evolutionary history. Of the four human-endemic common-cold coronaviruses, the two alphacoronaviruses 229E and NL63 are similar to SARS-CoV-2 in binding a protein receptor via the spike’s receptor-binding domain (RBD, also known as S1-B) (<xref ref-type="bibr" rid="R31">Hofmann et al., 2005</xref>; <xref ref-type="bibr" rid="R79">Walls et al., 2020</xref>; <xref ref-type="bibr" rid="R83">Yeager et al., 1992</xref>). In contrast, the two betacoronaviruses OC43 and HKU1 bind glycan receptors via the spike’s N-terminal domain (NTD, also known as S1-A) (<xref ref-type="bibr" rid="R33">Hulswit et al., 2019</xref>). Antibodies that block receptor binding dominate the neutralizing activity of immunity elicited by SARS-CoV-2 infection (<xref ref-type="bibr" rid="R1">Abe et al</xref>.; <xref ref-type="bibr" rid="R58">Piccoli et al., 2020</xref>; <xref ref-type="bibr" rid="R74">Tan et al., 2020</xref>), so we reasoned that even though SARS-CoV-2 is a betacoronavirus, its antigenic evolution is more likely to be foreshadowed by the two human alphacoronaviruses that also use their RBD to bind a protein receptor. Of these two viruses, we chose 229E since it has circulated in humans for &lt;50 years (<xref ref-type="bibr" rid="R27">Hamre and Procknow, 1966</xref>), whereas NL63 was only identified in 2003 (<xref ref-type="bibr" rid="R30">van der Hoek et al., 2004</xref>).</p>
<p id="P10">We inferred a phylogenetic tree of 229E spikes from direct or low-passage human isolates (<xref ref-type="fig" rid="F1">Figure 1A</xref>), excluding older strains passaged extensively in the lab (<xref ref-type="bibr" rid="R27">Hamre and Procknow, 1966</xref>). There are several important features of the tree. First, it is clock-like, with sequence divergence proportional to virus isolation date (<xref ref-type="fig" rid="F1">Figures 1A</xref> and <xref ref-type="supplementary-material" rid="SD1">S1</xref>). Second, the tree is “ladder-like,” with short branches off a single trunk (<xref ref-type="fig" rid="F1">Figure 1A</xref>). The ladder-like shape of the 229E phylogeny has been noted previously (<xref ref-type="bibr" rid="R12">Chibo and Birch, 2006</xref>; <xref ref-type="bibr" rid="R29">Hodcroft, 2020</xref>; <xref ref-type="bibr" rid="R39">Kistler and Bedford, 2020</xref>), and is a signature of viruses such as influenza for which immune pressure drives population turnover by selecting for antigenic variants (<xref ref-type="bibr" rid="R6">Bedford et al., 2011</xref>; <xref ref-type="bibr" rid="R20">Fitch et al., 1997</xref>). Third, sequences group by date rather than country of isolation (in <xref ref-type="fig" rid="F1">Figure 1A</xref>, sequences from different countries but the same year are nearby). Phylogenies that organize by date rather than geography indicate fast global transmission, another signature of human influenza virus (<xref ref-type="bibr" rid="R44">Lemey et al., 2014</xref>; <xref ref-type="bibr" rid="R57">Nelson et al., 2007</xref>). Finally, although there is some intra-spike recombination, it is among closely related strains and does not affect the broader topology of the tree (<xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>). For our study, the key implication of the above observations is that date of virus isolation is a good proxy for evolutionary position, since 229E evolves primarily along a single trajectory through time.</p>
<p id="P11">For our experiments, we chose five spikes from 229E viruses spaced at roughly 8-year intervals spanning 1984 to 2016 (<xref ref-type="fig" rid="F1">Figure 1A</xref>). We synthesized genes encoding all five spikes, truncating the last 19 residues of the cytoplasmic tail since this improves titers of spike-pseudotyped viruses (<xref ref-type="bibr" rid="R14">Crawford et al., 2020a</xref>; <xref ref-type="bibr" rid="R36">Kawase et al., 2009</xref>; <xref ref-type="bibr" rid="R64">Rogers et al., 2020</xref>). These five spikes differ by up to 4% in amino-acid sequence over their entire lengths, but are vastly more different in their RBDs, with 17% RBD divergence between 1984 and 2016 (<xref ref-type="fig" rid="F1">Figure 1B</xref>). We generated lentiviral particles pseudotyped with each spike, and found that all five supported high infectious titers in cells expressing 229E’s receptor aminopeptidase N (<xref ref-type="bibr" rid="R83">Yeager et al., 1992</xref>) and the activating protease TMPRSS2 (<xref ref-type="bibr" rid="R8">Bertram et al., 2013</xref>) (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>). Any major antigenic evolution by 229E since the 1980s should be captured by differences among these five spikes.</p>
</sec>
<sec id="S4">
<title>Neutralizing titers of historical sera drop rapidly against spikes from “future” viruses</title>
<p id="P12">To test if the 229E spikes had evolved to escape neutralization by human immunity, we used historical sera collected from adults between 1985 and 1990. Since the typical person is infected with 229E every 2–5 years (<xref ref-type="bibr" rid="R3">Aldridge et al., 2020</xref>; <xref ref-type="bibr" rid="R19">Edridge et al., 2020</xref>; <xref ref-type="bibr" rid="R68">Schmidt et al., 1986</xref>), many of these individuals should have been infected with 1984-like viruses within a few years preceding sera collection. None of the individuals would have been infected with any of the later viruses, since those viruses did not yet exist at the time of sera collection.</p>
<p id="P13">Nearly all sera collected from 1985–1990 had at least some neutralizing activity against viral particles pseudotyped with the 1984 spike (25 of 27 sera had titers &gt;1:10; <xref ref-type="supplementary-material" rid="SD1">Figures S4 and S5</xref>). We focused further analysis on the roughly 30% of sera (8 of 27) that had neutralizing titers against the 1984 spike of &lt;1:90 (<xref ref-type="supplementary-material" rid="SD1">Figure S5</xref>). Our reason for focusing on these sera is that their anti-229E neutralizing titers are comparable to anti-SARS-CoV-2 sera neutralizing titers several months after recovery from COVID-19 (<xref ref-type="bibr" rid="R14">Crawford et al., 2020a</xref>; <xref ref-type="bibr" rid="R78">Wajnberg et al., 2020</xref>) or receipt of the Moderna mRNA-1273 vaccine (<xref ref-type="bibr" rid="R81">Widge et al., 2020</xref>).</p>
<p id="P14">All sera that potently neutralized virions pseudotyped with the 1984 spike had reduced titers against more recent spikes (<xref ref-type="fig" rid="F2">Figure 2A</xref>). In some cases, the drop in neutralization of more recent spikes was dramatic. For instance, serum collected from a 28-year old in 1990 neutralized the 1984 spike at a titer of 1:125 but did not neutralize the 1992 spike at our limit of detection of 1:10 (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Similarly, serum collected from a 24-year old in 1987 neutralized the 1984 spike at 1:120 but barely neutralized the 1992 spike and did not detectably neutralize spikes more recent than 1992 (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Only 2 of 8 sera that potently neutralized the 1984 spike detectably neutralized all subsequent spikes, and only at greatly reduced titers against the most recent spikes.</p>
<p id="P15">To confirm that these results reflect antigenic evolution rather than some unique neutralization susceptibility of the 1984 spike, we repeated similar experiments using sera collected from 1992–1995 and initially screening for neutralization of the 1992 spike. Again, nearly all (18 of 19) sera detectably neutralized the 1992 spike, with about a quarter (5 of 19) having titers &lt;1:90 (<xref ref-type="supplementary-material" rid="SD1">Figures S4 and S5</xref>). These potent sera also neutralized the older 1984 spike with high titers, but again generally had lower activity against spikes from viruses isolated after the sera were collected (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Together, the results from the two sera collection timeframes indicate that the 229E spike is evolving antigenically, such that immunity elicited by infection with prior viruses is often ineffective at neutralizing future viruses.</p>
<p id="P16">To quantify the rate of antigenic evolution, for all sera in <xref ref-type="fig" rid="F2">Figure 2A,B</xref> we computed the drop in neutralization titer against spikes from one and two timepoints later relative to the contemporaneous spike. The median drop in titer was 4-fold against viruses from 8–9 years in the future, and &lt;6-fold for viruses 16–17 years in the future (<xref ref-type="fig" rid="F2">Figure 2C</xref>). However, these medians mask substantial serum-to-serum variation in neutralization of antigenically evolved future viruses. Neutralization by some sera is eroded &lt;10-fold by just 8–9 years of viral evolution, whereas neutralization by a few sera is unaffected even by 16–17 years of evolution.</p>
</sec>
<sec id="S5">
<title>Modern sera neutralize viruses that circulated throughout an individual’s lifetime</title>
<p id="P17">The above results show that viral antigenic evolution erodes the capacity of anti-229E immunity to neutralize the future descendants of the viruses that elicited the immunity. We next addressed a related question: does serum immunity durably retain the capacity to neutralize historical 229E strains that an individual was exposed to many years ago?</p>
<p id="P18">To address this question, we used modern sera collected in 2020 from children and adults. The adults were alive during circulation of all five 229E spikes in our panel (i.e., they were born before 1984), but the children could only have been exposed to the more recent spikes. We screened 31 modern sera against the 2016 spike, and found that 25 of 31 detectably neutralized at a threshold of 1:10 (<xref ref-type="supplementary-material" rid="SD1">Figures S4 and S5</xref>). We again focused further analysis on the more potent sera with titers &lt;1:90 (7 of 31 sera, <xref ref-type="supplementary-material" rid="SD1">Figure S5</xref>).</p>
<p id="P19">Modern adult sera that potently neutralized the 2016 spike also neutralized all prior spikes dating back to 1984 (<xref ref-type="fig" rid="F3">Figure 3</xref>). In contrast, the children’s sera neutralized spikes from viruses that circulated during the children’s lifetimes but often had reduced activity against spikes from before the children were born (<xref ref-type="fig" rid="F3">Figure 3</xref>). However, neutralization by children’s sera generally extends further “back in time” to viruses that preceded birth than neutralization by adult sera in <xref ref-type="fig" rid="F2">Figure 2A,B</xref> extends “forward in time” to viruses that circulated after the sera was collected. Similar time asymmetry in antigenic evolution has been described for influenza virus (<xref ref-type="bibr" rid="R66">Sandbulte et al., 2011</xref>). Overall, the results in <xref ref-type="fig" rid="F3">Figure 3</xref> show that neutralizing immunity can encompass the entire spectrum of spikes an individual has been exposed to, consistent with the notion that reduced neutralization of future viruses is due to antigenic evolution rather than a lack of durability in immunity itself.</p>
</sec>
<sec id="S6">
<title>Much of the antigenic evolution is due to mutations in the spike’s receptor-binding domain (RBD)</title>
<p id="P20">We next sought to identify the region(s) within the 229E spike where mutations drive antigenic drift. Coronavirus spikes consist of two subunits, S1 and S2, and it is well known that S2 is relatively conserved whereas S1 is more rapidly evolving (<xref ref-type="bibr" rid="R47">Liò and Goldman, 2004</xref>; <xref ref-type="bibr" rid="R77">Tortorici and Veesler, 2019</xref>). The S1 subunit itself consists of several domains, and we were inspired by several excellent papers by Rini and colleagues to pursue the hypothesis that 229E’s antigenic drift might be driven by amino-acid substitutions within the three loops in the S1 RBD that bind the receptor (<xref ref-type="bibr" rid="R46">Li et al., 2019</xref>; <xref ref-type="bibr" rid="R82">Wong et al., 2017</xref>).</p>
<p id="P21">We first calculated the protein sequence variability at each residue across an alignment of 229E spikes isolated between 1984 and 2019 (<xref ref-type="fig" rid="F4">Figure 4A</xref>). As expected, most sequence variability was in the S1 subunit, with particularly high variability in the three receptor-binding loops within the RBD (<xref ref-type="fig" rid="F4">Figure 4A</xref>). However, there was also substantial variability within some portions of the N-terminal domain (NTD) as well as other parts of the S1 subunit.</p>
<p id="P22">To experimentally test the extent that mutations in the RBD explained antigenic evolution, we created chimeras consisting of the 1984 spike with the RBD replaced by that of each of the four subsequent spikes. All these RBD-chimeric spikes supported efficient entry by pseudotyped viral particles (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>). We performed neutralization assays using the chimeric spikes against the sera from 1985–1990 that potently neutralized the 1984 spike (<xref ref-type="fig" rid="F4">Figure 4B</xref>). For all sera with neutralizing activity that was rapidly eroded by antigenic evolution, the drops in titer against more recent spikes were paralleled by drops in titer against the RBD-chimeric spikes (e.g., 26 and 24-year olds in <xref ref-type="fig" rid="F4">Figure 4B</xref>). However, this trend did not hold for some sera that were more resistant to antigenic evolution: for instance, serum from the 29-year old did not neutralize the 2016 spike, but neutralized the chimera with the 2016 RBD (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Overall, these results suggest that when the neutralizing activity of potent human sera is rapidly eroded by viral evolution this is often due to mutations within the RBD, but that antigenic evolution also occurs elsewhere in the spike. In this respect, it is worth noting that while the neutralizing activity of SARS-CoV-2 immunity elicited by infection primarily targets the RBD (<xref ref-type="bibr" rid="R58">Piccoli et al., 2020</xref>), mutations to the NTD also reduce neutralization by some antibodies and sera (<xref ref-type="bibr" rid="R11">Chi et al., 2020</xref>; <xref ref-type="bibr" rid="R37">Kemp et al., 2020</xref>; <xref ref-type="bibr" rid="R48">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="R51">McCarthy et al., 2020</xref>; <xref ref-type="bibr" rid="R80">Weisblum et al., 2020</xref>; <xref ref-type="bibr" rid="R85">Zhou et al., 2019</xref>)—and some regions of the NTD undergo significant sequence evolution in 229E (<xref ref-type="fig" rid="F4">Figure 4A</xref>).</p>
</sec>
</sec>
<sec id="S7" sec-type="discussion">
<title>Discussion</title>
<p id="P23">We have experimentally demonstrated that the spike of a human coronavirus evolves antigenically with sufficient speed to escape neutralization by many polyclonal human sera within one to two decades. This finding suggests that one reason that humans are repeatedly re-infected with seasonal coronaviruses may be that evolution of the viral spike erodes the immunity elicited by prior infections.</p>
<p id="P24">How does the rate of antigenic evolution of 229E compare to that of influenza virus? Remarkably, we could find no studies that measured how quickly influenza evolution erodes neutralization by human sera. However, numerous studies examine influenza antigenic evolution using hemagglutination-inhibition (HAI) assays with sera from ferrets infected with single viral strains (<xref ref-type="bibr" rid="R70">Smith et al., 2004</xref>). The rate at which 229E escapes neutralization by human sera is several fold slower than the rate at which influenza A/H3N2 escapes HAI by ferret sera, but comparable to the rate of such escape by influenza B (<xref ref-type="bibr" rid="R7">Bedford et al., 2014</xref>; <xref ref-type="bibr" rid="R56">Neher et al., 2016</xref>). However, the sera of ferrets infected by a single influenza virus strain tend to recognize fewer viral strains than sera from humans who have been repeatedly infected with many strains (<xref ref-type="bibr" rid="R21">Fonville et al., 2014</xref>, <xref ref-type="bibr" rid="R22">2016</xref>; <xref ref-type="bibr" rid="R45">Li et al., 2013</xref>). Therefore, ferret sera HAI may overestimate how quickly influenza evolution erodes neutralization by actual human sera. For this reason, further work is needed to enable head-to-head comparisons of antigenic evolution across these viruses.</p>
<p id="P25">The rapid antigenic evolution of the 229E spike might seem puzzling given that coronaviruses have a lower mutation rate than other RNA viruses (<xref ref-type="bibr" rid="R16">Denison et al., 2011</xref>; <xref ref-type="bibr" rid="R67">Sanjuán et al., 2010</xref>). But the rate of phenotypic evolution is not equal to mutation rate; evolution also depends on the effects of mutations and how selection acts on them. These other factors explain why influenza undergoes rapid antigenic evolution while measles does not, despite having a similar mutation rate. Specifically, mutations to influenza hemagglutinin are often well tolerated (<xref ref-type="bibr" rid="R76">Thyagarajan and Bloom, 2014</xref>), and single hemagglutinin mutations can have huge effects on escaping polyclonal sera (<xref ref-type="bibr" rid="R43">Lee et al., 2019</xref>). In contrast, measles surface proteins are less tolerant of mutations (<xref ref-type="bibr" rid="R23">Fulton et al., 2015</xref>), and the single mutations that are tolerated never more than modestly affect measles neutralization by polyclonal sera (<xref ref-type="bibr" rid="R54">Muñoz-Alía et al., 2020</xref>). In these respects, coronaviruses unfortunately seem more similar to influenza than measles. The neutralizing antibody response to SARS-CoV-2 is often focused on just a small portion of spike (<xref ref-type="bibr" rid="R5">Barnes et al., 2020</xref>; <xref ref-type="bibr" rid="R49">Liu et al., 2020b</xref>; <xref ref-type="bibr" rid="R58">Piccoli et al., 2020</xref>; <xref ref-type="bibr" rid="R80">Weisblum et al., 2020</xref>), and key receptor-binding loops are mutationally tolerant in the spikes of both 229E (<xref ref-type="bibr" rid="R46">Li et al., 2019</xref>; <xref ref-type="bibr" rid="R82">Wong et al., 2017</xref>) and SARS-CoV-2 (<xref ref-type="bibr" rid="R72">Starr et al., 2020a</xref>). Therefore, even though mutations to coronaviruses occur at a lower rate, they are acted on by selection in a fashion more similar to influenza than measles (<xref ref-type="bibr" rid="R39">Kistler and Bedford, 2020</xref>).</p>
<p id="P26">A striking aspect of our results is the extreme person-to-person variation in how rapidly neutralizing immunity is eroded by the evolution of coronavirus 229E. Some sera that potently neutralize contemporaneous virus have no detectable activity against viral strains isolated 8+ years later. But other sera maintain neutralizing activity against strains isolated over two decades later. This finding is reminiscent of how mutations to influenza virus can have vastly different effects on neutralization by sera from different individuals (<xref ref-type="bibr" rid="R43">Lee et al., 2019</xref>). Identifying what factors determine how rapidly an individual’s coronavirus immunity is eroded by viral mutations is an important area for future work, as it would obviously be desirable for SARS-CoV-2 vaccines to elicit immunity that is relatively robust to viral evolution.</p>
<p id="P27">The biggest question is what our work implies about possible antigenic evolution by SARS-CoV-2. While it is impossible to know if SARS-CoV-2 will evolve similarly to 229E, it is ominous that mutations affecting neutralization by antibodies or sera are already present at low frequencies among circulating SARS-CoV-2 (<xref ref-type="bibr" rid="R26">Greaney et al., 2020</xref>; <xref ref-type="bibr" rid="R37">Kemp, 2020</xref>; <xref ref-type="bibr" rid="R49">Liu et al., 2020b</xref>; <xref ref-type="bibr" rid="R51">McCarthy et al., 2020</xref>; <xref ref-type="bibr" rid="R73">Starr et al., 2020b</xref>; <xref ref-type="bibr" rid="R75">Thomson, 2020</xref>; <xref ref-type="bibr" rid="R80">Weisblum et al., 2020</xref>) even though most of the human population is still naive and so presumably exerting little immune pressure on the virus. But two facts provide hope even in light of our observation that human coronaviruses evolve to escape neutralizing immunity. First, the level of immunity required to prevent severe COVID-19 may be low (<xref ref-type="bibr" rid="R59">Polack et al., 2020</xref>), perhaps because the slower course of disease provides more time for a recall immune response than for “quicker” viruses such as influenza. An optimistic interpretation is that disease might often be mild even if viral antigenic evolution allows re-infections. Second, many leading SARS-CoV-2 vaccines use new technologies such as mRNA-based delivery (<xref ref-type="bibr" rid="R41">Krammer, 2020</xref>) that should make it easy to update the vaccine if there is antigenic evolution in spike. For this reason, we suggest that SARS-CoV-2 evolution should be monitored for antigenic mutations that might make it advisable to periodically update vaccines.</p>
</sec>
<sec id="S8" sec-type="methods">
<title>Methods</title>
<sec id="S9">
<title>Data and computer code availability</title>
<p id="P28">The data and computer code for all phylogenetic analyses and experiments are on GitHub at <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift">https://github.com/jbloomlab/CoV_229E_antigenic_drift</ext-link>
</underline>. Relevant parts of this GitHub repository are called out in the Methods below; in addition the repository itself includes a README that aids in navigation. All paper figures can be generated using the computer code and data in this repository.</p>
</sec>
<sec id="S10">
<title>Phylogenetic analysis of 229E spikes</title>
<p id="P29">To assemble a set of 229E spikes, we downloaded all accessions for “Human coronavirus 229E (taxid:1137)” available from NCBI Virus as of July-13-2020. These accessions are listed at <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/NCBI_Virus_229E_accessions.csv">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/NCBI_Virus_229E_accessions.csv</ext-link>
</underline>. The NCBI information for some sequence accessions (particularly older sequences) were missing metadata that was available in publications describing the sequences (<xref ref-type="bibr" rid="R11">Chibo and Birch, 2006</xref>; <xref ref-type="bibr" rid="R69">Shirato et al., 2012</xref>). For these accessions, we manually extracted the relevant metadata from the publications (see <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/extra_229E_accessions_metadata.yaml">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/extra_229E_accessions_metadata.yaml</ext-link>
</underline>). We also identified a few sequences that were clear outliers on the date-to-tip regression in the analyses described below, and so are probably mis-annotations; these accessions were excluded (see <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/accessions_to_include_exclude_annotate.yaml">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/accessions_to_include_exclude_annotate.yaml</ext-link>
</underline>).</p>
<p id="P30">We parsed full-length human-isolate spikes encoding unique proteins from this sequence set (see <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/results/get_parse_spikes.md">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/results/get_parse_spikes.md</ext-link>),</underline> used mafft (<xref ref-type="bibr" rid="R35">Katoh and Standley, 2013</xref>) to align the protein sequences, and used a custom Python script (<underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/prot_to_codon_alignment.py">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/prot_to_codon_alignment.py</ext-link>
</underline>) to build a codon alignment from the protein alignment (File S1). We used GARD (<xref ref-type="bibr" rid="R40">Kosakovsky Pond et al., 2006</xref>; <xref ref-type="bibr" rid="R71">Spielman et al., 2019</xref>) to screen for recombination (see tanglegram in <xref ref-type="supplementary-material" rid="SD1">Figure S2</xref> and code at <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/results/gard_tanglegram.md">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/results/gard_tanglegram.md</ext-link>
</underline>).</p>
<p id="P31">The phylogenetic tree topology was inferred using IQ-TREE (<xref ref-type="bibr" rid="R53">Minh et al., 2020</xref>) using a codon-substitution model (<xref ref-type="bibr" rid="R55">Muse and Gaut, 1994</xref>) with a transition-transversion ratio and F3X4 empirical codon frequencies. We then used TreeTime (<xref ref-type="bibr" rid="R65">Sagulenko et al., 2018</xref>) to root the tree (<xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>) and also re-scale the branch lengths for the time tree in <xref ref-type="fig" rid="F1">Figure 1A</xref>. The tree images were rendered using ETE 3 (<xref ref-type="bibr" rid="R32">Huerta-Cepas et al., 2016</xref>).</p>
<p id="P32">To compute the variability at each site in spike (<xref ref-type="fig" rid="F4">Figure 4A</xref>), we used the same alignment as for the phylogenetic analysis. We then computed the amino-acid variability at each site as the effective number of amino acids, which is the exponential of the Shannon entropy (<xref ref-type="bibr" rid="R18">Echave and Wilke, 2017</xref>). The domains of spike were annotated using the definitions in (<xref ref-type="bibr" rid="R46">Li et al., 2019</xref>), which are provided at <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/AAK32191_hand_annotated.gp">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/AAK32191_hand_annotated.gp</ext-link>
</underline>.</p>
</sec>
<sec id="S11">
<title>Plasmids encoding 229E spikes and RBD chimeras</title>
<p id="P33">The protein sequences of the spikes used in the experiments are in File S2. We deleted the last 19 amino acids of the spike’s C-terminus (in the cytoplasmic tail) as this modification has been reported (<xref ref-type="bibr" rid="R14">Crawford et al., 2020a</xref>; <xref ref-type="bibr" rid="R36">Kawase et al., 2009</xref>; <xref ref-type="bibr" rid="R64">Rogers et al., 2020</xref>) and validated in our hands (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>) to improve titers of virions pseudotyped with spike. For the 1984, 1992, 2001, 2008, and 2016 spikes, the protein sequence matches the Genbank sequences for these viral strains (<xref ref-type="fig" rid="F1">Figure 1A</xref> and File S1) except for the tail deletion. For the RBD chimeras, we annotated domains of spike as in (<xref ref-type="bibr" rid="R46">Li et al., 2019</xref>); see <ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/AAK32191_hand_annotated.gp">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/data/AAK32191_hand_annotated.gp</ext-link>. We then designed the RBD-chimera proteins by replacing the RBD of the 1984 spike with the RBD of each of the 1992, 2001, 2008, and 2016 spikes.</p>
<p id="P34">We designed human-codon-optimized gene sequences encoding each of these spike proteins using the tool provided by Integrated DNA Technologies, had the genes synthesized commercially, and cloned them into a CMV-driven expression plasmid. Genbank sequences of the resulting plasmids are at <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/tree/master/exptl_data/plasmid_maps">https://github.com/jbloomlab/CoV_229E_antigenic_drift/tree/master/exptl_data/plasmid_maps</ext-link>
</underline>. The names of the plasmids are listed below (note how the names include “delta19” or “d19” to indicate the C-terminal deletion as well as the year for that viral strain and whether it is a chimera; note also that we created a plasmid for the 2016 spike that did not have the C-terminal deletion for the experiments in <xref ref-type="supplementary-material" rid="SD1">Figure S3</xref> that validated the benefits of the deletion): <list list-type="bullet" id="L1">
<list-item>
<p id="P35">HDM-229E-Spike-d19-1984</p>
</list-item>
<list-item>
<p id="P36">HDM-229E-Spike-d19-1992</p>
</list-item>
<list-item>
<p id="P37">HDM-229E-Spike-d19-2001</p>
</list-item>
<list-item>
<p id="P38">HDM-229E-Spike-d19-2008</p>
</list-item>
<list-item>
<p id="P39">HDM-229E-Spike-Seattle2016</p>
</list-item>
<list-item>
<p id="P40">HDM-229E-Spike-delta19-Seattle2016</p>
</list-item>
<list-item>
<p id="P41">HDM-229E-Spike-d19-1984-1992RBD</p>
</list-item>
<list-item>
<p id="P42">HDM-229E-Spike-d19-1984-2001RBD</p>
</list-item>
<list-item>
<p id="P43">HDM-229E-Spike-d19-1984-2008RBD</p>
</list-item>
<list-item>
<p id="P44">HDM-229E-Spike-d19-1984-2016RBD</p>
</list-item>
</list>
</p>
</sec>
<sec id="S12">
<title>Generation and titering of 229E spike-pseudotyped lentiviral particles encoding luciferase and ZsGreen</title>
<p id="P45">We generated spike-pseudotyped lentiviral particles using the same approach that we have recently described for SARS-CoV-2 (<xref ref-type="bibr" rid="R14">Crawford et al., 2020a</xref>, <xref ref-type="bibr" rid="R15">2020b</xref>). This approach involves creating pseudotyped lentiviral particles by transfecting cells with a plasmid expressing spike, a plasmid expressing a lentiviral backbone encoding luciferase and ZsGreen, and plasmids expressing the other lentiviral proteins necessary for virion formation (<xref ref-type="bibr" rid="R14">Crawford et al., 2020a</xref>, <xref ref-type="bibr" rid="R15">2020b</xref>). The only modifications for this study are that we used the plasmids expressing the 229E spike described above rather than plasmids expressing the SARS-CoV-2 spike, and that after producing the pseudotyped lentiviral particles we infected them into target cells engineered to be infectable by the 229E spike.</p>
<p id="P46">Specifically, the 229E spike binds to human aminopeptidase N (APN) to initiate viral entry (<xref ref-type="bibr" rid="R83">Yeager et al., 1992</xref>). To make 293T cells infectable by 229E, we therefore transiently transfected them with an APN protein expression plasmid (SinoBiological, NM_001150.2) prior to seeding the cells for infection. To further promote lentiviral infection, we simultaneously transiently transfected them with a plasmid encoding transmembrane serine protease 2 (TMPRSS2), which facilitates 229E-spike mediated viral entry by cleaving and activating the spike (<xref ref-type="bibr" rid="R8">Bertram et al., 2013</xref>). We used the TMPRSS2-expressing plasmid pHAGE2_EF1aInt_TMPRSS2_IRES_mCherry (<xref ref-type="bibr" rid="R42">Lee et al., 2018</xref>).</p>
<p id="P47">For titering the spike-pseudotyped particles in these cells, we used the following procedure. To mitigate any possible well-to-well differences in transfection efficiency in a 96-well plate format, we first bulk transfected a dish of 293T cells, followed by seeding the 96-well plates routinely used in neutralization assays and viral titering. Specifically, an approximately 90% confluent 10 cm dish of 293T cells was transfected with 8.5 μg APN-expressing plasmid, 1 μg of TMPRSS2-expressing plasmid, and 0.5 μg of carrier DNA (Promega, E4881) to achieve an 8.5:1 ratio of APN:TMPRSS2. We found that this ratio gave sufficient TMPRSS2 expression, while maintaining low levels of cell toxicity. Cells were transfected using the Bioland Scientific BioT transfection reagent following the manufacturer’s protocol but incubating transfection complexes for 15 minutes at room temperature instead of the recommended 5 minutes as we have anecdotally observed that this extended incubation increases transfection efficiency. After 5–6 hours, transfection supernatant was removed and the APN and TMPRSS2-transfected 293T cells were trypsinized (Fisher, MT25053CI). Cells were then seeded in clear bottom, black-walled, poly-L-lysine coated 96-well plates that were either professionally pre-coated (Greiner, 655936) or hand-coated (Greiner, 655090) with poly-L-lysine solution (Millipore Sigma, P4704) at 1.75x10e4 cells per well in 50 μL D10 growth media (DMEM with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin). Plates were incubated at 37℃ with 5% CO<sub>2</sub> for 20–24 hours, and cells were infected with serial 2-fold serial dilutions of the pseudotyped lentiviral particles. These viral dilutions were made in TC-treated “set-up” 96-well plates and then transferred to the pre-seeded 293T-ACE2-TMPRSS2 cells from the previous day.</p>
<p id="P48">Approximately 50–52 hours later, we quantified infection by reading the luminescence signal produced from the luciferase encoded in the lentiviral backbone. Specifically, 100 μL of media in each well was removed—while being sure to leave the cells undisturbed—leaving approximately 30 μL of media left over. Then an equal volume of Bright-Glo reagent (Promega, E2610) was added to the remaining 30 uL of media in each well and the solution was mixed up and down to ensure complete cell lysis. In order to minimize the potential for premature luciferase excitation, special care was taken to protect the assay plates from light. Mainly, assay plate preparation was performed in a biosafety hood with the lights off and plates were covered in tin foil after the addition of the luciferase reagent. The luminescence was then measured on a TECAN Infinite M1000 Pro plate reader with no attenuation and a luminescence integration time of 1 s. <xref ref-type="supplementary-material" rid="SD1">Figure S3</xref> shows the titers achieved for each 229E spike variant, and also demonstrates the importance of the spike cytoplasmic tail deletion and the expression of APN and TMPRSS2 for efficient viral infection. Note that for one panel in <xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>, we instead determined the titer by using flow cytometry to detect the fraction of cells expressing the ZsGreen also encoded in the lentiviral backbone.</p>
</sec>
<sec id="S13">
<title>Human sera</title>
<p id="P49">All sera used in this study, along with relevant metadata (e.g., collection date, patient age, and the measured neutralization titer against each assayed virus) are listed in File S3, which is also available at <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/exptl_data/results/all_neut_titers.csv">https://github.com/jbloomlab/CoV_229E_antigenic_drift/blob/master/exptl_data/results/all_neut_titers.csv</ext-link>
</underline>.</p>
<p id="P50">Most of the historical human sera from the 1980s and 1990s are identified by the prefix SD in File S3 (e.g., SD85_1). These sera were obtained from the Infectious Disease Sciences Biospecimen Repository at the Vaccine and Infectious Disease Division (VIDD) of the Fred Hutchinson Cancer Research Center in Seattle, WA, and were collected from prospective bone marrow donors with approval from the Human Subjects Institutional Review Board. A few of the historical sera are residual samples obtained from Bloodworks Northwest that were collected from adults in Seattle; these sera are identified by the prefix FH in File S3 (e.g., FH007TR). A few of the sera were collected from subjects with exact ages that were unknown, but were adults old enough to have been alive in 1984 (the isolation year of the first spike in our panel).</p>
<p id="P51">The modern children’s sera from 2020 are identified by the prefix POP_ in File S3 (e.g., POP_0007), and are residual sera collected at Seattle Children’s Hospital in Seattle, WA, in March of 2020 with approval from the Human Subjects Institutional Review Board. Each of these serum samples is from a unique individual who was confirmed to be seronegative for SARS-CoV-2 by an anti-RBD ELISA (<xref ref-type="bibr" rid="R17">Dingens et al., 2020</xref>).</p>
<p id="P52">The modern adult sera from 2020 are identified by the prefix AUSAB (e.g., AUSAB-01) in File S3, and are residual sera from University of Washington Lab Medicine that were collected for testing for HBsAb (for which they tested negative).</p>
<p id="P53">For a negative control, we used serum from a goat that had not been infected with the 229E human coronavirus; namely WHO goat serum (FR-1377) procured from the International Reagent Resource.</p>
<p id="P54">All sera were heat inactivated prior to use by incubation at 56℃ for approximately 30 minutes.</p>
</sec>
<sec id="S14">
<title>Neutralization assays</title>
<p id="P55">The 293T cells used for our neutralization assays were transfected to express APN and TMPRSS2 and seeded as for the viral titering described above. The neutralization assays were set up at 20–24 hours after seeding of the cells into 96-well plates. First, the heat-inactivated serum samples were diluted 1:10 in D10 growth media followed by 3-fold serial dilutions in TC-coated 96-well “set-up” plates, ultimately giving seven total dilutions per sample. These dilutions were done in duplicate for each serum sample. Each 229E spike-pseudotyped lentivirus was then diluted to achieve luciferase readings of approximately 200,000 RLUs per well (the exact dilution factor varied among viruses due to differences in titers; see <xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>). An equal volume of virus was then added to each well of the virus plus sera “set-up” plates, and these plates were incubated for 1 hour at 37℃ with 5% CO <sub>2</sub>, after which 100 uL of each virus plus sera mixture were transferred to the 293T-APN-TMPRSS2 cell plate that had been seeded the day prior. Plates were incubated at 37℃ with 5% CO <sub>2</sub> for approximately 50-52 hours, and then the luciferase signal was read as described above for viral titering.</p>
<p id="P56">Each neutralization plate contained a column of positive control wells consisting of cells plus virus incubated with D10 media but no sera, and a negative control consisting of virus but no cells (we also confirmed that using a cells-only negative control gave similar results). The fraction infectivity was computed at each serum dilution as the fraction of the signal for the positive control (averaged across the two positive control wells for each row) after subtracting the background reading for the negative control. We then fit 2-parameter Hill curves with baselines fixed to 1 and 0 using neutcurve (<underline>
<ext-link ext-link-type="uri" xlink:href="https://jbloomlab.github.io/neutcurve/">https://jbloomlab.github.io/neutcurve/</ext-link>
</underline>). Note that the serum concentration reported in these curves is the concentration at which the virus was pre-incubated with the sera for 1 hour. All of the neutralization curves are plotted in <xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>. All of the IC50s are tabulated in File S3. See <underline>
<ext-link ext-link-type="uri" xlink:href="https://github.com/jbloomlab/CoV_229E_antigenic_drift/tree/master/exptl_data">https://github.com/jbloomlab/CoV_229E_antigenic_drift/tree/master/exptl_data</ext-link>
</underline> for raw and processed plate reader data and all of the computer code used for the fitting. Note that all assays were done in duplicate, but some sera-virus pairs have additional readings as we re-ran selected sera-virus pairs to confirm that results remained consistent across different assay days. In all cases the day-to-day consistency was good, and the reported values are the mean IC50s across all assays.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Information</label>
<media xlink:href="EMS108922-supplement-Supplementary_Information.pdf" mimetype="application" mime-subtype="pdf" id="N66965" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S15">
<title>Acknowledgments</title>
<p>We thank David Veesler, Allison Greaney, Tyler Starr, Kathryn Kistler, and Trevor Bedford for helpful comments. This work was supported by the NIH / NIAID under grants R01AI127983 and R01AI141707 (to JDB), and F30AI149928 (to KHDC). We also thank the Vaccine and Infectious Diseases Division of the Fred Hutch for supporting the biorepository used for the 1980s and 1990s sera. JDB is an Investigator of the Howard Hughes Medical Institute.</p>
</ack>
<fn-group>
<fn id="FN1" fn-type="conflict">
<p id="P57">
<bold>Competing interests</bold>
</p>
<p id="P58">MJB has consulted for Moderna and Vir Biotechnologies, and received research funding from Regeneron and Vir Biotechnologies. JAE has consulted for Meissa Vaccines and Sanofi Pasteur, and received research funding from Merck, GlaxoSmithKline, Pfizer, and AstraZeneca. The other authors declare no competing interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Samson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Samavarchi-Tehrani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Valcourt</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Budylowski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Girardin</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Rathod</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>A simple protein-based surrogate neutralization assay for SARS-CoV-2</article-title>
<source>JCI Insight</source>
<volume>5</volume>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addetia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Roychoudhury</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M-L</given-names>
</name>
<name>
<surname>Jerome</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Greninger</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate</article-title>
<source>J Clin Microbiol</source>
<year>2020</year>
<volume>58</volume>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aldridge</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Lewer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Beale</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Zambon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Fragaszy</surname>
<given-names>EB</given-names>
</name>
<collab>Flu Watch Group</collab>
</person-group>
<article-title>Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study</article-title>
<source>Wellcome Open Res</source>
<year>2020</year>
<volume>5</volume>
<fpage>52</fpage>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alsoussi</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rizk</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>McIntire</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection</article-title>
<source>J Immunol</source>
<year>2020</year>
<volume>205</volume>
<fpage>915</fpage>
<lpage>922</lpage>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Huey-Tubman</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>MAG</given-names>
</name>
<name>
<surname>Sharaf</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Koranda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gristick</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>828</fpage>
<lpage>842.e16</lpage>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cobey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pascual</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Strength and tempo of selection revealed in viral gene genealogies</article-title>
<source>BMC Evol Biol</source>
<year>2011</year>
<volume>11</volume>
<fpage>220</fpage>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suchard</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lemey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dudas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gregory</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>McCauley</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Integrating influenza antigenic dynamics with molecular evolution</article-title>
<source>ELife</source>
<year>2014</year>
<volume>3</volume>
<fpage>e01914</fpage>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertram</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dijkman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Habjan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heurich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gierer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Glowacka</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Welsch</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hofmann-Winkler</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium</article-title>
<source>J Virol</source>
<year>2013</year>
<volume>87</volume>
<fpage>6150</fpage>
<lpage>6160</lpage>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callow</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection</article-title>
<source>J Hyg (Lond.)</source>
<year>1985</year>
<volume>95</volume>
<fpage>173</fpage>
<lpage>189</lpage>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callow</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Sergeant</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tyrrell</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>The time course of the immune response to experimental coronavirus infection of man</article-title>
<source>Epidemiol Infect</source>
<year>1990</year>
<volume>105</volume>
<fpage>435</fpage>
<lpage>446</lpage>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>650</fpage>
<lpage>655</lpage>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chibo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains</article-title>
<source>J Gen Virol</source>
<year>2006</year>
<volume>87</volume>
<fpage>1203</fpage>
<lpage>1208</lpage>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couch</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Kasel</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Immunity to influenza in man</article-title>
<source>Annu Rev Microbiol</source>
<year>1983</year>
<volume>37</volume>
<fpage>529</fpage>
<lpage>549</lpage>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Wilcox</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Logue</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Shuey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Casto</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Fiala</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wrenn</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection</article-title>
<source>J Infect Dis</source>
<year>2020a</year>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays</article-title>
<source>Viruses</source>
<year>2020b</year>
<volume>12</volume>
<fpage>513</fpage>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denison</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Eckerle</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Baric</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Coronaviruses</article-title>
<source>RNA Biol</source>
<year>2011</year>
<volume>8</volume>
<fpage>270</fpage>
<lpage>279</lpage>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Amanat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<comment>4378</comment>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Echave</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wilke</surname>
<given-names>CO</given-names>
</name>
</person-group>
<article-title>Biophysical Models of Protein Evolution: Understanding the Patterns of Evolutionary Sequence Divergence</article-title>
<source>Annu Rev Biophys</source>
<year>2017</year>
<volume>46</volume>
<fpage>85</fpage>
<lpage>103</lpage>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edridge</surname>
<given-names>AWD</given-names>
</name>
<name>
<surname>Kaczorowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoste</surname>
<given-names>ACR</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Loens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jebbink</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Matser</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kinsella</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rueda</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Seasonal coronavirus protective immunity is short-lasting</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>1691</fpage>
<lpage>1693</lpage>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Fitch</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Long term trends in the evolution of H(3) HA1 human influenza type A</article-title>
<conf-name>Proc Natl Acad Sci U S A</conf-name>
<year>1997</year>
<volume>94</volume>
<fpage>7712</fpage>
<lpage>7718</lpage>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonville</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wilks</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>James</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ventresca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aban</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>H</surname>
<given-names>LNM</given-names>
</name>
<name>
<surname>T</surname>
<given-names>PQ</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody landscapes after influenza virus infection or vaccination</article-title>
<source>Science</source>
<year>2014</year>
<volume>346</volume>
<fpage>996</fpage>
<lpage>1000</lpage>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonville</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fraaij</surname>
<given-names>PLA</given-names>
</name>
<name>
<surname>de Mutsert</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wilks</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>van Beek</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RAM</given-names>
</name>
<name>
<surname>Rimmelzwaan</surname>
<given-names>GF</given-names>
</name>
</person-group>
<article-title>Antigenic Maps of Influenza A(H3N2) Produced With Human Antisera Obtained After Primary Infection</article-title>
<source>J Infect Dis</source>
<year>2016</year>
<volume>213</volume>
<fpage>31</fpage>
<lpage>38</lpage>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fulton</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Beaty</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Palese</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Heaton</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins</article-title>
<source>Cell Rep</source>
<year>2015</year>
<volume>11</volume>
<fpage>1331</fpage>
<lpage>1338</lpage>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tokuyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ladinsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaefer-Babajew</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Evolution of Antibody Immunity to SARS-CoV-2</article-title>
<source>BioRxiv</source>
<year>2020</year>
<comment>2020.11.03.367391</comment>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galili</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>dendextend: an R package for visualizing, adjusting and comparing trees of hierarchical clustering</article-title>
<source>Bioinformatics</source>
<year>2015</year>
<volume>31</volume>
<fpage>3718</fpage>
<lpage>3720</lpage>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Loes</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Huddleston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<etal/>
</person-group>
<article-title>Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition</article-title>
<source>Cell Host Microbe</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Hamre</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Procknow</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>A New Virus Isolated from the Human Respiratory Tract</article-title>
<conf-name>Proc Soc Exp Biol Med</conf-name>
<year>1966</year>
<volume>121</volume>
<fpage>190</fpage>
<lpage>193</lpage>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Hendley</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Fishburne</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Jack M Gwaltney</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Coronavirus Infections in Working Adults</article-title>
<conf-name>Am Rev Respir Dis</conf-name>
<year>1972</year>
<source>105</source>
<fpage>805</fpage>
<lpage>811</lpage>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Hodcroft</surname>
<given-names>EB</given-names>
</name>
</person-group>
<source>Seasonal CoV and SARS CoV live full-genome builds</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Hoek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pyrc</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jebbink</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Vermeulen-Oost</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Berkhout</surname>
<given-names>RJM</given-names>
</name>
<name>
<surname>Wolthers</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Wertheim-van Dillen</surname>
<given-names>PME</given-names>
</name>
<name>
<surname>Kaandorp</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spaargaren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berkhout</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Identification of a new human coronavirus</article-title>
<source>Nat Med</source>
<year>2004</year>
<volume>10</volume>
<fpage>368</fpage>
<lpage>373</lpage>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hofmann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pyrc</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van der Hoek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Geier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berkhout</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pöhlmann</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2005</year>
<volume>102</volume>
<fpage>7988</fpage>
<lpage>7993</lpage>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huerta-Cepas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bork</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>ETE 3: Reconstruction, Analysis, and Visualization of Phylogenomic Data</article-title>
<source>Mol Biol Evol</source>
<year>2016</year>
<volume>33</volume>
<fpage>1635</fpage>
<lpage>1638</lpage>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hulswit</surname>
<given-names>RJG</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bakkers</surname>
<given-names>MJG</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Schouten</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ophorst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van Kuppeveld</surname>
<given-names>FJM</given-names>
</name>
<name>
<surname>Boons</surname>
<given-names>G-J</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>B-J</given-names>
</name>
<etal/>
</person-group>
<article-title>Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2019</year>
<volume>116</volume>
<fpage>2681</fpage>
<lpage>2690</lpage>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibarrondo</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Fulcher</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Goodman-Meza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hofmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hausner</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ferbas</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Tobin</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Aldrovandi</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>OO</given-names>
</name>
</person-group>
<article-title>Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<fpage>1085</fpage>
<lpage>1087</lpage>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Standley</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability</article-title>
<source>Mol Biol Evol</source>
<year>2013</year>
<volume>30</volume>
<fpage>772</fpage>
<lpage>780</lpage>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawase</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shirato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Protease-Mediated Entry via the Endosome of Human Coronavirus 229E</article-title>
<source>J Virol</source>
<year>2009</year>
<volume>83</volume>
<fpage>712</fpage>
<lpage>721</lpage>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemp</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion | medRxiv</article-title>
<source>BioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemp</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Datir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gayed</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jahun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hosmillo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rees-Spear</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mlcochova</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lumb</surname>
<given-names>IU</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion</article-title>
<source>MedRxiv</source>
<year>2020</year>
<comment>2020.12.05.20241927</comment>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kistler</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses | bioRxiv</article-title>
<source>BioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosakovsky Pond</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Posada</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gravenor</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Woelk</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>SDW</given-names>
</name>
</person-group>
<article-title>GARD: a genetic algorithm for recombination detection</article-title>
<source>Bioinformatics</source>
<year>2006</year>
<volume>22</volume>
<fpage>3096</fpage>
<lpage>3098</lpage>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krammer</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 vaccines in development</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<fpage>516</fpage>
<lpage>527</lpage>
</element-citation>
</ref>
<ref id="R42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Huddleston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doud</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2018</year>
<volume>115</volume>
<fpage>E8276</fpage>
<lpage>E8285</lpage>
</element-citation>
</ref>
<ref id="R43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Eguia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stevens-Ayers</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boeckh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hurt</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lakdawala</surname>
<given-names>SS</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin</article-title>
<source>ELife</source>
<year>2019</year>
<volume>8</volume>
<fpage>e49324</fpage>
</element-citation>
</ref>
<ref id="R44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Faria</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bielejec</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baele</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Pybus</surname>
<given-names>OG</given-names>
</name>
<name>
<surname>Brockmann</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Unifying Viral Genetics and Human Transportation Data to Predict the Global Transmission Dynamics of Human Influenza H3N2</article-title>
<source>PLOS Pathog</source>
<year>2014</year>
<volume>10</volume>
<fpage>e1003932</fpage>
</element-citation>
</ref>
<ref id="R45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Bostick</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Madara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Linderman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Wrammert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Immune history shapes specificity of pandemic H1N1 influenza antibody responses</article-title>
<source>J Exp Med</source>
<year>2013</year>
<volume>210</volume>
<fpage>1493</fpage>
<lpage>1500</lpage>
</element-citation>
</ref>
<ref id="R46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Tomlinson</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Desforges</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Benlekbir</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rini</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>The human coronavirus HCoV-229E S-protein structure and receptor binding</article-title>
<source>ELife</source>
<year>2019</year>
<volume>8</volume>
<fpage>e51230</fpage>
</element-citation>
</ref>
<ref id="R47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liò</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Phylogenomics and bioinformatics of SARS-CoV</article-title>
<source>Trends Microbiol</source>
<year>2004</year>
<volume>12</volume>
<fpage>106</fpage>
<lpage>111</lpage>
</element-citation>
</ref>
<ref id="R48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JF-W</given-names>
</name>
<name>
<surname>Sahi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</article-title>
<source>Nature</source>
<year>2020a</year>
<volume>584</volume>
<fpage>450</fpage>
<lpage>456</lpage>
</element-citation>
</ref>
<ref id="R49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Rothlauf</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Bloyet</surname>
<given-names>L-M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Stumpf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Errico</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Theel</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Ellebedy</surname>
<given-names>AH</given-names>
</name>
<etal/>
</person-group>
<article-title>Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title>
<source>BioRxiv</source>
<year>2020b</year>
<comment>2020.11.06.372037</comment>
</element-citation>
</ref>
<ref id="R50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lumley</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stoesser</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Howarth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hatch</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>S</given-names>
</name>
<name>
<surname>James</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibodies to SARS-CoV-2 are associated with protection against reinfection</article-title>
<source>MedRxiv</source>
<year>2020</year>
<comment>2020.11.18.20234369</comment>
</element-citation>
</ref>
<ref id="R51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Rennick</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Nambulli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robinson-McCarthy</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Bain</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Haidar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Duprex</surname>
<given-names>WP</given-names>
</name>
</person-group>
<article-title>Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape</article-title>
<source>BioRxiv</source>
<year>2020</year>
<comment>2020.11.19.389916</comment>
</element-citation>
</ref>
<ref id="R52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mercado</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tostanoski</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Chandrashekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Atyeo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>
<source>Nature</source>
<year>2020</year>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minh</surname>
<given-names>BQ</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Chernomor</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Schrempf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Woodhams</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>von Haeseler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lanfear</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era</article-title>
<source>Mol Biol Evol</source>
<year>2020</year>
<volume>37</volume>
<fpage>1530</fpage>
<lpage>1534</lpage>
</element-citation>
</ref>
<ref id="R54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muñoz-Alía</surname>
<given-names>M.Á</given-names>
</name>
<name>
<surname>Nace</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Pathogenic measles viruses cannot evolve to bypass vaccine-induced neutralizing antibodies</article-title>
<source>BioRxiv</source>
<year>2020</year>
<comment>2020.10.22.351189</comment>
</element-citation>
</ref>
<ref id="R55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muse</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Gaut</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>A likelihood approach for comparing synonymous and nonsynonymous nucleotide substitution rates, with application to the chloroplast genome</article-title>
<source>Mol Biol Evol</source>
<year>1994</year>
<volume>11</volume>
<fpage>715</fpage>
<lpage>724</lpage>
</element-citation>
</ref>
<ref id="R56">
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Neher</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bedford</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Shraiman</surname>
<given-names>BI</given-names>
</name>
</person-group>
<article-title>Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses</article-title>
<conf-name>Proc Natl Acad Sci</conf-name>
<year>2016</year>
<volume>113</volume>
<fpage>E1701</fpage>
<lpage>E1709</lpage>
</element-citation>
</ref>
<ref id="R57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Simonsen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Viboud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>EC</given-names>
</name>
</person-group>
<article-title>Phylogenetic Analysis Reveals the Global Migration of Seasonal Influenza A Viruses</article-title>
<source>PLOS Pathog</source>
<year>2007</year>
<volume>3</volume>
<fpage>e131</fpage>
</element-citation>
</ref>
<ref id="R58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccoli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silacci-Fregni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>1024</fpage>
<lpage>1042.e21</lpage>
</element-citation>
</ref>
<ref id="R59">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polack</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kitchin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pérez Marc</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Zerbini</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>0</volume>
<comment>null</comment>
</element-citation>
</ref>
<ref id="R60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranjeva</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Subramanian</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>DKM</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>RAPM</given-names>
</name>
<name>
<surname>Peiris</surname>
<given-names>JSM</given-names>
</name>
<name>
<surname>Cowling</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Cobey</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Age-specific differences in the dynamics of protective immunity to influenza</article-title>
<source>Nat Commun</source>
<year>2019</year>
<volume>10</volume>
<comment>1660</comment>
</element-citation>
</ref>
<ref id="R61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reed</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E-related strains</article-title>
<source>J Med Virol</source>
<year>1984</year>
<volume>13</volume>
<fpage>179</fpage>
<lpage>192</lpage>
</element-citation>
</ref>
<ref id="R62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Paranhos-Baccalà</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Genetic drift of human coronavirus OC43 spike gene during adaptive evolution</article-title>
<source>Sci Rep</source>
<year>2015</year>
<volume>5</volume>
<comment>11451</comment>
</element-citation>
</ref>
<ref id="R63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodda</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Netland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shehata</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pruner</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Morawski</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Thouvenel</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Takehara</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Eggenberger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hemann</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Waterman</surname>
<given-names>HR</given-names>
</name>
<etal/>
</person-group>
<article-title>Functional SARS-CoV-2-specific immune memory persists after mild COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Beutler</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>A</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Limbo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Woehl</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>956</fpage>
<lpage>963</lpage>
</element-citation>
</ref>
<ref id="R65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sagulenko</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Puller</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Neher</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>TreeTime: Maximum-likelihood phylodynamic analysis</article-title>
<source>Virus Evol</source>
<year>2018</year>
<volume>4</volume>
</element-citation>
</ref>
<ref id="R66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandbulte</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Westgeest</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Klimov</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RAM</given-names>
</name>
<name>
<surname>Eichelberger</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses</article-title>
<source>Proc Natl Acad Sci</source>
<year>2011</year>
<volume>108</volume>
<fpage>20748</fpage>
<lpage>20753</lpage>
</element-citation>
</ref>
<ref id="R67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanjuán</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nebot</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Chirico</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mansky</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Belshaw</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Viral Mutation Rates</article-title>
<source>J Virol</source>
<year>2010</year>
<volume>84</volume>
<fpage>9733</fpage>
<lpage>9748</lpage>
</element-citation>
</ref>
<ref id="R68">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>OW</given-names>
</name>
<name>
<surname>Allan</surname>
<given-names>ID</given-names>
</name>
<name>
<surname>Cooney</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Foy</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Rises in titers of antibody to human corona viruses OC43 and 229E in Seattle families during 1975-1979</article-title>
<source>Am J Epidemiol</source>
<year>1986</year>
<volume>123</volume>
<fpage>862</fpage>
<lpage>868</lpage>
</element-citation>
</ref>
<ref id="R69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hirokawa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Differences in neutralizing antigenicity between laboratory and clinical isolates of HCoV-229E isolated in Japan in 2004–2008 depend on the S1 region sequence of the spike protein</article-title>
<source>J Gen Virol</source>
<year>2012</year>
<volume>93</volume>
<fpage>1908</fpage>
<lpage>1917</lpage>
</element-citation>
</ref>
<ref id="R70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Lapedes</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Jong</surname>
<given-names>JC de</given-names>
</name>
<name>
<surname>Bestebroer</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Rimmelzwaan</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Osterhaus</surname>
<given-names>ADME</given-names>
</name>
<name>
<surname>Fouchier</surname>
<given-names>RAM</given-names>
</name>
</person-group>
<article-title>Mapping the Antigenic and Genetic Evolution of Influenza Virus</article-title>
<source>Science</source>
<year>2004</year>
<volume>305</volume>
<fpage>371</fpage>
<lpage>376</lpage>
</element-citation>
</ref>
<ref id="R71">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Spielman</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shank</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Magalis</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kosakovsky Pond</surname>
<given-names>SL</given-names>
</name>
</person-group>
<chapter-title>Evolution of Viral Genomes: Interplay Between Selection, Recombination, and Other Forces</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Anisimova</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Evolutionary Genomics: Statistical and Computational Methods</source>
<publisher-loc>New York, NY</publisher-loc>
<publisher-name>Springer</publisher-name>
<year>2019</year>
<fpage>427</fpage>
<lpage>468</lpage>
</element-citation>
</ref>
<ref id="R72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHD</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding</article-title>
<source>Cell</source>
<year>2020a</year>
<volume>182</volume>
<fpage>1295</fpage>
<lpage>1310.e20</lpage>
</element-citation>
</ref>
<ref id="R73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Addetia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hannon</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Choudhary</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Prospective mapping of viral mutations that escape antibodies used to treat COVID-19</article-title>
<source>BioRxiv Prepr Serv Biol</source>
<year>2020b</year>
</element-citation>
</ref>
<ref id="R74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>MI-C</given-names>
</name>
<name>
<surname>Tiu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>VC-W</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Sia</surname>
<given-names>WR</given-names>
</name>
<etal/>
</person-group>
<article-title>A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction</article-title>
<source>Nat Biotechnol</source>
<year>2020</year>
<volume>38</volume>
<fpage>1073</fpage>
<lpage>1078</lpage>
</element-citation>
</ref>
<ref id="R75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomson</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity | bioRxiv</article-title>
<source>BioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thyagarajan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin</article-title>
<source>ELife</source>
<year>2014</year>
<volume>3</volume>
<fpage>e03300</fpage>
</element-citation>
</ref>
<ref id="R77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structural insights into coronavirus entry</article-title>
<source>Adv Virus Res</source>
<year>2019</year>
<volume>105</volume>
<fpage>93</fpage>
<lpage>116</lpage>
</element-citation>
</ref>
<ref id="R78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wajnberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Amanat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Firpo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Meade</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mendu</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Muellers</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Robust neutralizing antibodies to SARS-CoV-2 infection persist for months</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>1227</fpage>
<lpage>1230</lpage>
</element-citation>
</ref>
<ref id="R79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>281</fpage>
<lpage>292.e6</lpage>
</element-citation>
</ref>
<ref id="R80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>DaSilva</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Poston</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rutkowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>H-H</given-names>
</name>
<name>
<surname>Michailidis</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title>
<source>ELife</source>
<year>2020</year>
<volume>9</volume>
<fpage>e61312</fpage>
</element-citation>
</ref>
<ref id="R81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widge</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Rouphael</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Makhene</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chappell</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Denison</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination</article-title>
<source>N Engl J Med</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>AHM</given-names>
</name>
<name>
<surname>Tomlinson</surname>
<given-names>ACA</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Satkunarajah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sharon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Desforges</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Rini</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Receptor-binding loops in alphacoronavirus adaptation and evolution</article-title>
<source>Nat Commun</source>
<year>2017</year>
<volume>8</volume>
<comment>1735</comment>
</element-citation>
</ref>
<ref id="R83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeager</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Ashmun</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Cardellichio</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Look</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>KV</given-names>
</name>
</person-group>
<article-title>Human aminopeptidase N is a receptor for human coronavirus 229E</article-title>
<source>Nature</source>
<year>1992</year>
<volume>357</volume>
<fpage>420</fpage>
<lpage>422</lpage>
</element-citation>
</ref>
<ref id="R84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tsibane</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McGraw</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>House</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Keefer</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Hicar</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Tumpey</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Pappas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors</article-title>
<source>Nature</source>
<year>2008</year>
<volume>455</volume>
<fpage>532</fpage>
<lpage>536</lpage>
</element-citation>
</ref>
<ref id="R85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein</article-title>
<source>Nat Commun</source>
<year>2019</year>
<volume>10</volume>
<comment>3068</comment>
</element-citation>
</ref>
<ref id="R86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Nkolola</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reidy</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Trivette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<etal/>
</person-group>
<article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>443</fpage>
<lpage>449</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Spikes used in this study. (A) Phylogenetic tree of 229E spikes, with tips colored by the country from which the virus was isolated. The spikes used in the experiments are indicated with black text and square shapes. The tree is a maximum-likelihood inference with IQ-TREE (Minh et al., 2020) with a codon-substitution model and re-scaled with TreeTime (Sagulenko et al., 2018) to position tips by to date of isolation. Figure S1 shows a tree with branch lengths proportional to divergence rather than time, and validates clock-like evolution. Figure S2 shows recombination does not substantially affect the phylogenetic placements of the spikes used in the experiments. (B) Protein sequence divergence of the spikes used in the experiments, computed over just the receptor-binding domain (RBD) or the full sequence. Divergence is the Levenshtein distance between the amino-acid sequences divided by the number of sites.</p>
</caption>
<graphic xlink:href="EMS108922-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>The neutralizing activity of human sera is lower against “future” viruses than those that elicited the immunity. (A) Sera collected between 1985 and 1990 was tested in neutralization assays against spikes from viruses isolated between 1984 and 2016. Each plot facet is a different serum, and black points show its neutralizing titer against viruses from the indicated year. Blue shading indicates the portion of plotted timeframe during which the individual could have been infected prior to serum collection. The dotted gray horizontal line indicates the limit of detection (titer of 1:10). Plot titles give the year of serum collection, the individual’s age when the serum was collected, and the serum ID. (B) Plots like those in (A) but for sera collected between 1993 and 1995. (C) The fold change in neutralization titer against viruses isolated 8–9 or 16–17 years in the “future” relative to the virus isolated just before the serum was collected. Box plots show the median and interquartile range, and each point is the fold change for a single serum. For a few sera (triangles), the fold change is censored (as an upper bound) because the titer against the future virus was below the limit of detection.</p>
</caption>
<graphic xlink:href="EMS108922-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Neutralizing titers of sera collected in 2020 are higher against historical viruses that circulated during an individual’s lifetime than viruses isolated before the individual was born. As in <xref ref-type="fig" rid="F2">Figure 2A</xref>,<xref ref-type="fig" rid="F2">B</xref>, each plot facet is a different serum with the title giving the individual’s age and black points indicating the titer against spikes from viruses isolated in the indicated year. Blue shading represents the portion of the plotted timeframe during which the individual was alive: for adults this is the entire timeframe, but for children the left edge of the blue shading indicates the birth year.</p>
</caption>
<graphic xlink:href="EMS108922-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Antigenic evolution is primarily due to changes in the spike’s receptor binding domain (RBD). (A) At top is a schematic of the 229E spike. Within the S1 subunit, the schematic indicates the N-terminal domain (NTD, also known as S1-A) and the RBD (also known as S1-B). The three loops in the RBD that bind the virus’s APN receptor are indicated (Li et al., 2019). Below the schematic is a plot of sequence variability across the alignment of 229E spikes in <xref ref-type="fig" rid="F1">Figure 1A</xref>. Variability is quantified as the effective number of amino acids at a site (Echave and Wilke, 2017), with a value of one indicating complete conservation and larger values indicating more sequence variability. (B) Neutralizing titers of sera collected between 1985 and 1990 against either the full spike of “future” viruses or chimeras consisting of the 1984 spike containing the RBD from “future” viruses. The plot format and the black circles (full spike) are repeated from <xref ref-type="fig" rid="F2">Figure 2A</xref> with the addition of the orange triangles showing the titers against the chimeric spikes.</p>
</caption>
<graphic xlink:href="EMS108922-f004"/>
</fig>
</floats-group>
</article>
